Figure 1. Completion of Follow-up.

^aParticipants were not formally screened prior to obtaining informed consent.

^bInformation was not collected on specific reasons for exclusion.

^cParticipants with 2 eyes in the study had 1 eye randomly assigned to receive ranibizumab and 1 eye receive panretinal photocoagulation.

^dTwo-year completed visits include those that occurred between 92 and 116 weeks.

^eThree-year completed visits include those that occurred between 148 and 164 weeks.

^fFour-year completed visits include those that occurred between 196 and 220 weeks.

^gFive-year completed visits include those that occurred between 248 and 272 weeks.